Insulin-like Growth Factor-1, IGF-binding Protein-3, C-peptide and Colorectal Cancer: a Case-control Study

  • Joshi, Pankaj (Department of Preventive Medicine, Kangwon National University School of Medicine) ;
  • Joshi, Rakhi Kumari (Department of Preventive Medicine, Kangwon National University School of Medicine) ;
  • Kim, Woo Jin (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Lee, Sang-Ah (Department of Preventive Medicine, Kangwon National University School of Medicine)
  • Published : 2015.05.18


Context: Insulin-like growth factor peptides play important roles in regulating cell growth, cell differentiation, and apoptosis, and have been demonstrated to promote the development of colorectal cancer (CRC). Objective: To examine the association of insulin-related biomarkers including insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) and C-peptide with CRC risk and assess their relevance in predictive models. Materials and Methods: The odds ratios of colorectal cancer for serum levels of IGF-1, IGFBP-3 and C-peptide were estimated using unconditional logistic regression models in 100 colorectal cancer cases and 100 control subjects. Areas under the receiving curve (AUC) and integrated discrimination improvement (IDI) statistics were used to assess the discriminatory potential of the models. Results: Serum levels of IGF-1 and IGFBP-3 were negatively associated with colorectal cancer risk (OR=0.07, 95%CI: 0.03-0.16, P for trend <.01, OR=0.06, 95%CI: 0.03-0.15, P for trend <.01 respectively) and serum C-peptide was positively associated with risk of colorectal cancer (OR=4.38, 95%CI: 2.13-9.06, P for trend <.01). Compared to the risk model, prediction for the risk of colorectal cancer had substantially improved when all selected biomarkers IGF-1, IGFBP-3 and inverse value of C-peptide were simultaneously included inthe reference model [P for AUC improvement was 0.02 and the combined IDI reached 0.166% (95 % CI; 0.114-0.219)]. Conclusions: The results provide evidence for an association of insulin-related biomarkers with colorectal cancer risk and point to consideration as candidate predictor markers.


Colorectal cancer;insulin-related biomarkers (IGF-1, IGFBP-3, C-peptide);case-control study


Supported by : National Research Foundation of Korea (NRF)


  1. Davies M, Gupta S, Goldspink G, et al (2006). The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. Int J Colorectal Dis, 21, 201-8.
  2. DeLong ER, DeLong DM, Clarke-Pearson DL (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 44, 837-45.
  3. Durai R, Yang W, Gupta S, et al (2005). The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis, 20, 203-20.
  4. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  5. Ferry RJ, Jr., Cerri RW, Cohen P (1999). Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res, 51, 53-67.
  6. Firth SM, Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev, 23, 824-54.
  7. Giovannucci E (2001). Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr, 131, 3109-20.
  8. Giovannucci E, Pollak MN, Platz EA, et al (2000). A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev, 9, 345-9.
  9. Gunter MJ, Hoover DR, Yu H, et al (2008). Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res, 68, 329-37.
  10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  11. Jenab M, Riboli E, Cleveland RJ, et al (2007). Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer, 121, 368-76.
  12. Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405.
  13. Kaaks R (2004). Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp, 262, 247-60.
  14. Kaaks R, Toniolo P, Akhmedkhanov A, et al (2000). Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst, 92, 1592-600.
  15. Kabat GC, Kim MY, Strickler HD, et al (2012). A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br J Cancer, 106, 227-32.
  16. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 21, 215-44.
  17. Ma J, Giovannucci E, Pollak M, et al (2004). A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst, 96, 546-53.
  18. Ma J, Pollak MN, Giovannucci E, et al (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst, 91, 620-5.
  19. Nomura AM, Stemmermann GN, Lee J, et al (2003). Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol, 158, 424-31.
  20. Ollberding NJ, Cheng I, Wilkens LR, et al (2012). Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study. Cancer Epidemiol Biomarkers Prev, 21, 810-20.
  21. Otani T, Iwasaki M, Sasazuki S, et al (2007). Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer, 120, 2007-12.
  22. Palmqvist R, Hallmans G, Rinaldi S, et al (2002). Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut, 50, 642-6.
  23. Palmqvist R, Stattin P, Rinaldi S, et al (2003). Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer, 107, 89-93.
  24. Pollak M (2000). Insulin-like growth factor physiology and cancer risk. Eur J Cancer, 36, 1224-8.
  25. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28.
  26. Probst-Hensch NM, Yuan JM, Stanczyk FZ, et al (2001). IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer, 85, 1695-9.
  27. Renehan AG, Zwahlen M, Minder C, et al (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363, 1346-53.
  28. Rinaldi S, Cleveland R, Norat T, et al (2010). Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer, 126, 1702-15.
  29. Sandhu MS, Dunger DB, Giovannucci EL (2002). Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst, 94, 972-80.
  30. Schoen RE, Tangen CM, Kuller LH, et al (1999). Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst, 91, 1147-54.
  31. Tran TT, Naigamwalla D, Oprescu AI, et al (2006). Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology, 147, 1830-7.
  32. Wei EK, Ma J, Pollak MN, et al (2005). A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev, 14, 850-5.

Cited by

  1. Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma vol.34, pp.3, 2015,